# Comprehensive Review of Cannabis & Cannabinoid Research Journal > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-cannabinoid-research-journal-clinical-evidence/ > **Published:** 2026-08-13T07:20:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:34-04:00 > **Clinical Summary:** Explore the cannabis cannabinoid research journal for emerging clinical evidence and insights on pharmacology and therapeutic applications. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCHempSafetyNeurologyMental Health Dr. Caplan’s Take “This journal publishes across a wide spectrum of evidence quality, from basic science to [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/), so any practitioner reading it needs to carefully distinguish between preliminary laboratory findings and rigorous human studies before integrating claims into clinical practice. The impact factor reflects solid peer review, but that doesn’t mean every paper carries equal weight for [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/) decisions.” Clinical Perspective 🔬 Cannabis & [Cannabinoid Research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) serves as an important peer-reviewed forum for emerging evidence on [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/) and clinical applications, though clinicians should recognize that the field remains fragmented with variable study quality and limited long-term safety data. The journal’s moderate impact factor and interdisciplinary scope reflect both genuine scientific progress and the heterogeneity of [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/), which spans basic chemistry, preclinical models, and small [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) with differing methodologies and patient populations. Key confounders include the wide variation in cannabinoid ratios, delivery methods, dosing regimens, and individual genetic factors affecting [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/) that make generalizing findings across studies challenging. Practitioners considering cannabinoid-based interventions should use this journal selectively as one evidence source while maintaining awareness that most published research remains preliminary, regulatory approval remains limited for most conditions, and robust head-to-head comparisons with established treatments are still scarce 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20%26amp%3B%20Cannabinoid%20Research%20-%20All%20Issues%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73277)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73277)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20%26amp%3B%20Cannabinoid%20Research%20-%20All%20Issues%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73277)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 …](https://cedclinic.com/artelo-announces-enrollment-of-first-patient-in-a-phase-2-clinical-trial-evaluating-art27-13/) - [Texas THC Ban Remains as Federal Judge Denies Emergency Pause](https://cedclinic.com/texas-thc-ban-federal-court-emergency-motion/) - [Does Cannabis Cause Erectile Dysfunction? *f0CyOc237*](https://cedclinic.com/does-cannabis-cause-erectile-dysfunction-f0cyoc237/) 📰 Source: [https://journals.sagepub.com/loi/ccb/group/d2010.y2017](https://journals.sagepub.com/loi/ccb/group/d2010.y2017) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New Clinical Insights on Cannabis and Patient Outcomes](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) Discover recent clinical insights on cannabis and how they impact patient outcomes in various therapeutic areas. [Read More](https://cedclinic.com/new-clinical-insights-on-cannabis-and-patient-outcomes/) [Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13](https://cedclinic.com/artelo-announces-enrollment-of-first-patient-in-a-phase-2-clinical-trial-evaluating-art27-13/) Stay updated on the latest phase 2 clinical trial evaluating ART27.13, a promising cannabinoid-based therapeutic candidate. [Learn More](https://cedclinic.com/artelo-announces-enrollment-of-first-patient-in-a-phase-2-clinical-trial-evaluating-art27-13/) [Q&A: What does science say about plants as medicine?](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) Explore scientific perspectives on the medicinal use of plants, including cannabis and cannabinoids, in clinical practice. [Explore Q&A](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).